Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05030298 · ClinicalTrials.gov registry record · Phase 1
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
A Phase 1 study of Malignant Glioma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05030298: Recruiting Phase 1 study of Malignant Glioma, sponsored by Mayo Clinic.
NCT05030298 is a Phase 1 study of Malignant Glioma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 28 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05030298, a Phase 1 study of Malignant Glioma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pre-operative radiosurgery may improve the odds of brain tumor control and reduce treatment-related side effects.
Primary Outcome
Assessed per Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0. The toxicity rate will be estimated using a binomial estimator and a one-sided 95% confidence interval (CI) of the rate will be computed with normal approximation.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Temozolomide
- RADIATION Radiosurgery
- PROCEDURE Stereotactic Biopsy
- PROCEDURE Tumor Treating Fields Therapy
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Phoenix
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-05-23 |
| Est. Completion | 2027-09-15 |
| Phase | Phase 1 |
What NCT05030298 shows while recruiting
NCT05030298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 5 interventions - of which Radiation Therapy is the first listed.
NCT05030298 reports a single indexed study location in Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05030298 about?
NCT05030298 is a clinical study titled "Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial". This phase I trial finds out the possible benefits and/or side effects of radiosurgery before surgery (preoperative) in treating patients with high grade glioma. Radiosurgery uses special equipment to position the patient and precisely give a single large dose of radiation to the tumor. This method ...
What is the current status of trial NCT05030298?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-05-23. Estimated completion is 2027-09-15.
What conditions does trial NCT05030298 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT05030298?
The interventions under investigation include: Radiation Therapy (RADIATION), Temozolomide (DRUG), Radiosurgery (RADIATION), Stereotactic Biopsy (PROCEDURE), Tumor Treating Fields Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT05030298?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05030298 being conducted?
This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05030298's enrollment target sits among peer trials
28 28th of 40 higher than 12 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI